<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Dans, Antonio Miguel</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Increased Bleeding Risk with Concomitant Use of Antiplatelet Therapy: Dabigatran vs Warfarin</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">24-25</style></pages><abstract><style  face="normal" font="default" size="100%">The RE-LY trial compared two doses of dabigatran (110 mg BID and 150 mg BID) with open label warfarin (target INR 2 to 3) in 18,113 patients with nonvalvular atrial fibrillation. This post hoc subanalyses from RE-LY, compares the efficacy and safety of dabigatran with warfarin in patients dependent upon use of concomitant antiplatelet therapy.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>